Clinical Professor of Medicine
Oncology
Dr. Przemyslaw Twardowski, MD
|
|
Give Review
Przemyslaw Twardowski works in the field of Oncology. He researched medicine at University of Missouri-Columbia School of Medicine. He has 4 awards "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer" and "Top Doctors:Southern California". Przemyslaw Twardowski is a published doctor and has 48 publications published. The lastest was: 'The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.' He is registered with Medicare and accepts Medicare payments.
Publications
- Activity of enzalutamide in men with metastatic castration-resistant prostate Cancer is affected by prior treatment with abiraterone and/or docetaxel.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial Carcinoma.
- Papillary Renal Cell Carcinoma: Current Progress and Future Directions.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.
- A phase II trial of dasatinib in patients with metastatic castration-resistant prostate Cancer treated previously with chemotherapy.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
- Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast Cancer.
- Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective Analysis☆
- Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urol...
- Human prostate carcinoma Cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
- The mechanism of Cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
- Clinical trials of antiangiogenic agents.
- A phase I study of bortezomib and temozolomide in patients with advanced solid Tumors.
- Prostate Cancer. Clinical practice guidelines in oncology.
- What are the indications for sorafenib treatment in patients with renal Cell carcinoma?
- Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
- A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate Cancer patients with bone metastases.
- Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell Cancer.
- Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
- Angiogenesis-targeted therapies in prostate Cancer.
- Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malign...
- Prognostic indicators and survival in patients with stage IIIB inflammatory breast Carcinoma after dose-intense chemotherapy.
- Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
- A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate Cancer.
- Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacoki...
- Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
- HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
- Occult primary Cancer clinical practice guidelines.
- Guideline for 5-alpha-reductase inhibitors in the prevention of prostate Cancer is premature.
- Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
- Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
- A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate Cancer: a California Cancer Consortium study.
- Oral fenretinide in biochemically recurrent prostate Cancer: a California Cancer consortium phase II trial.
- Bevacizumab plus interferon alpha in patients with metastatic renal Cell carcinoma.
- The AKT inhibitor perifosine in biochemically recurrent prostate Cancer: a phase II California/Pittsburgh Cancer consortium trial.
- Nursing considerations with pazopanib therapy: focus on metastatic renal Cell carcinoma.
- A phase II trial of gefitinib and pegylated IFNα in previously treated renal Cell carcinoma.
- Critical appraisal of cabazitaxel in the management of advanced prostate Cancer.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- NCCN clinical practice guidelines in oncology: prostate Cancer.
- Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory b...
- Primary gonadal germ cell tumor associated with Acute leukemia with common cytogenetics.
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional Cell carcinoma of the urothelium.
- Biologic markers of angiogenesis: circulating endothelial Cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and cel...
Schools
University Of Missouri
Northwestern Meml Hospital
Northwestern University Medical School
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
Education
-
McGaw Medical Center of Northwestern University -
University of Missouri-Columbia School of Medicine
Hospital
-
City of Hope's Helford Clinical Research Hospital
Drug Facts
| NPI NUMBER | 1942317987 | |
| NPPES Provider LastName | TWARDOWSKI | |
| NPPES Provider FirstName | PRZEMYSLAW | |
| NPPES Provider ZIPCode | 91010 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 284.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 5.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942317987 |
| Last Name Of The Provider | TWARDOWSKI |
| First Name Of The Provider | PRZEMYSLAW |
| View All |
Similar Doctors
|
Dr. Sanjay Awasthi, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Mihaela Cristea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucille Leong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vincent Chung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arvind M. Shinde, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuan Yuan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marianna Koczywas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thehang H. Luu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eduardo P. Siccion, MD
This Doctor is OpenDoctor Recommended.
|